Could a common blood pressure drug boost radiation against tough pancreatic tumors?
NCT ID NCT04106856
First seen May 15, 2026 · Last updated May 15, 2026
Summary
This early-phase study tests whether adding the blood pressure drug losartan to a shorter, stronger course of radiation can help treat pancreatic cancer that is either hard to remove surgically or has spread nearby. Losartan may improve blood flow and oxygen in the tumor, making radiation more effective. About 22 adults with this type of pancreatic cancer will receive the combination after standard chemotherapy, and researchers will monitor side effects closely.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE III PANCREATIC CANCER AJCC V8 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Huntsman Cancer Institute/University of Utah
Salt Lake City, Utah, 84112, United States
Conditions
Explore the condition pages connected to this study.